GH Stock Recent News
GH LATEST HEADLINES
Guardant Health (GH) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.67 per share a year ago.
Beyond analysts' top -and-bottom-line estimates for Guardant Health (GH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Cathie Wood bought shares of Guardant Health, Oklo, and CRISPR Technologies on Tuesday. Guardant is the only one of the three trading higher this year, fueled by the prospects of a new colorectal cancer screening tool.
Guardant Health Inc.'s stock rose 2.4% Monday, after the company said the Food and Drug Administration has approved its blood test for colon-cancer screening in adults 45 and older who are at average risk for the disease.
Guardant Health (GH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Guardant Health (GH) on Monday said that its Shield colorectal cancer-screening blood test has received approval from the U.S. Food and Drug Administration (FDA), sending shares higher.
On Monday, the FDA approved Guardant Health Inc.'s GH Shield blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease.
Shares of Guardant Health jumped 7% on Monday, after the Food and Drug Administration approved the company's blood test to screen for colon cancer, a new testing method the company said is intended to boost the rate of screenings for the disease as fewer eligible Americans opt for colonoscopies.
The U.S. Food and Drug Administration on Monday approved Guardant Health's blood test to detect a cancer that starts in the colon or rectum.
PALO ALTO, Calif.--(BUSINESS WIRE)--The FDA has approved the Shield test from Guardant Health, the first blood test approved as a primary screening option for colorectal cancer.